Key words Compositae - anti-inflammatory activity - research - patents - products
Introduction
Compositae is considered one of the most numerous and evolved families of the plant kingdom, as well as the largest family of flowering plants. Its name derives from the characteristic structure of its inflorescences, in the form of flower head [1 ]. Paul Dietrich Giseke stated that Compositae includes more than 1600 genera and 23 000 species [2 ], [3 ], of which 250 genera and 2000 species are found in Brazil. These plants have varied habits and may be herbs, shrubs, trees, and creepers, although small plants predominate [1 ].
The Compositae family has a cosmopolitan distribution and is widespread in all continents except for Antarctica [4 ], [5 ] and easily encountered in savannas, the countryside, and less frequently in humid tropical forests [2 ]. This family has great economic utility for food, cosmetics, and pharmaceutics as an ornamental plant and also includes plants with phytoremediation potential [4 ], [6 ]. In addition to this strong economic impact, other species of this family have been the target of speculation because they can cure different diseases. Many have been used in popular medicine, such as arnica (Arnica montana ), macela (Achyrocline satureioides (Lam.) DC.), globe artichoke (Cynara scolymus ), and guaco (Mikania glomerata var glomerata ), which are widely used, respectively, for healing, anti-inflammatory,
hepatic insufficiency, and respiratory problems [7 ].
Individual species of the Compositae family have been the subjects of reviews about their anti-inflammatory activity. However, no review has emphasized the technological prospection of the Compositae family, including the most important species with anti-inflammatory activity, highlighting scientific articles involving the development of pharmaceutical forms, patents, and products on the market.
In Brazil, several species of the Compositae family are indicated for different pathologies in popular medicine, largely as anti-inflammatories, in official compendia such as the Memento Fitoterápico da Farmacopeia Brasileira (MFFB, Phytotherapic Summary of Brazilian Pharmacopoeia) [8 ] and in the Formulário Fitoterápico da Farmacopeia Brasileira (FFFB, Phytotherapic Formulations of Brazilian Pharmacopoeia) [9 ]. In addition, the Brazilian government, through Normative Instruction IN 02/2014 [10 ], lists traditional phytotherapeutic products for simplified registration, where a list of recommended species with anti-inflammatory activity, such as Calendula officinalis, Matricaria chamomilla , and Arnica montana are present [11 ]. The latter, in Brazil, is a substitute species, Solidago chilensis , which is recommended in the
Relação Nacional de Plantas de Interesse do Sistema Único de Saúde (RENISUS, Brazilian National List of Medicinal Plants by the Unified Public Health System [12 ], both with anti-inflammatory activity [13 ].
Dutra et al. [14 ] recently made a survey on the use of medicinal plants in Brazil, contemplating pharmacological studies, discovery of new drugs, challenges, and perspectives. The anti-inflammatory activity was one of the relevant indices of continual study by researchers, in which some species from Compositae were included.
However, according to Carvalho et al. [15 ], although the market for natural products has expanded worldwide, Brazil does not seem to have participated in this expansion, since few products from Brazilian biodiversity have been licensed. Currently, one of the obstacles for finding phytotherapeutic products licensed in Brazil could be the complexity of the entire production chain for phytomedicines, as well as the transferring of basic research to the industrial scale and the communication between those involved in this process [16 ], [17 ].
Thus, one of the objectives of this work was to evaluate how much of the basic research is currently translated into products registered on the market or for perspective production, through patent protection.
Focusing on species in the Compositae family with anti-inflammatory activity, a study of the therapeutic potential was conducted by surveying scientific articles, theses, dissertations, patent applications, patents granted, and products on the market. This work surveyed the Integrity Platform databases (Derwent, Web of Science, and SciELO) in Science Direct, Lilacs, and PubMed, as well as consulted the National Health Regulatory Agency (ANVISA, Agência Nacional de Vigilância Sanitária ) site to verify the products with valid registration of these species.
In spite of the numerous Compositae species found with anti-inflammatory activity, some were more relevant than others, especially when comparing the number of bibliographic references with the requested patents and products in the market. The majority with a registered product are already used by traditional herbal medicine and are included in official compendia or in the national list of plants of SUS interest.
This work reviews reports published between 2008 – 2018 in the databases Science Direct, Lilacs and PubMed, as well as in the databases of the Integrity Platform, as in the main collection of scientific articles of the Web of Science and SciELO Citation Index. Patents were also searched on the basis of the Integrity Platform, in the Derwent Innovation Index, which indexed over 62 patent authorities in the Derwent World Patent Index featuring as clients United States Patents and Trademark Office (USPTO), European Patent Office (EPO), Japan Patent Office (JPO), Brazil among others, covering over 98% of all basic patents in the world. The search covered a period from 1998 to 2018, encompassing the 20-y patent period. To obtain a scientific, patent, and market survey of the species of the Compositae family with anti-inflammatory activity, the possible products registered in Brazil were also searched on the ANVISA website.
For the databases of scientific articles, the following keywords and combinations were used: Compositae, anti-inflammatory activity, pharmaceutical preparations, tablets, capsules, syrups, compresses, nanoformulations, nanoparticles, solutions and suspensions, creams, gels, and semi-solid formulations. In general, searches were refined in terms of the Plant Science or Pharmacology and Pharmacy subjects, mainly looking for open access articles and reviews, although some computed references were not automatically available either. In addition, relevant theses and dissertations found outside the search but within the stipulated chronological period were incorporated into this research. Only studies with full descriptions were considered and presented; thus, evaluated references included part of the plant used, extraction and isolation method, and phytochemical identification about the marker through chromatographic and spectroscopic assays. Another relevant criterion evaluated
was the intention to develop pharmaceutical products for internal or external use, thereby reducing the number of papers presented. In addition, references that showed in vitro anti-inflammatory potential and in vivo anti-inflammatory activity assays for extracts and/or isolated substances as well as for formulated products were considered relevant.
Patenting monitoring contemplated the same keywords or combination of these and considered formulations and compositions for the International Patent Classification (IPC) such as A61 (medical or veterinary science, hygiene), A61K (preparations for medical, dental, or hygienic), A61P (therapeutic activities of medicinal preparations), as well as the years and country of deposit.
On the Anvisa site, the products researched were the species with the greatest description of potential anti-inflammatory action observed through the articles and patents found in the databases, or its popular indication, using the word “phytoterapic”, as a regulatory category.
Metric Comparison between Databases
Metric Comparison between Databases
In all the databases surveyed, a search for the term Compositae brought up innumerable and countless references. However, this general search proved the lack of a review article on technological prospection of the Compositae family with anti-inflammatory activity that highlighted scientific articles, patents, and commercial products.
[Fig. 1 ] shows the number of records found in the databases searched between 2008 and 2018 for scientific articles, dissertations, and theses, as well as for the years 1998 – 2018 for patents, when terms for anti-inflammatory activity were searched.
Fig. 1 Relation of the number of records found in the searched databases combining search terms with anti-inflammatory activity.
In most of the sources, when the terms Compositae and anti-inflammatory activity are combined, many references appear, especially in the main collection of Web of Sciences. Nevertheless, when these terms are combined with some pharmaceutical forms, few appeared, except in the Science Direct database, where for the pharmaceutical form “drug solution”, this number was quite expressive compared to the others (27). This same graph illustrates that although the number of articles is high for Compositae with anti-inflammatory activity, the patents and products from species of this family does not follow that trend, which confirms the information of Carvalho et al. [15 ] who mention that the market for biodiversity products is still very small.
In addition to the solutions, the most commonly cited pharmaceutical forms were gels and creams. However, when the search was carried out, generalizing the pharmaceutical forms as pharmaceutical preparations, this number was also high.
Species of the Compositae Family Found with Anti-Inflammatory Activity or with Anti-Inflammatory Potential
Species of the Compositae Family Found with Anti-Inflammatory Activity or with Anti-Inflammatory Potential
[Table 1 ] shows a compilation of the references containing several Compositae species with anti-inflammatory activity as a function of different inflammation models (in vivo ) or with anti-inflammatory potential, through the effects on mediators of the inflammatory processes (in vitro ). All the descriptors of the mentioned species are in agreement with The Plant List taxonomic database.
Table 1 Compositae species with anti-inflammatory activity (in vivo ) or with effects on mediators of the inflammatory processes (in vitro ), under different models.
Species name by genus
Plant part used/starting material
Markers
Extract type/ Pharmaceutical form/Isolated Substance
Experimental condition or assay carried out
Ref
The anti-inflammatory activity (in vivo ) was evaluated, in most cases, in different edema models, or in specific models such as:
a
arthritis/gout;
b
anti-asthmatic;
c
wound healing;
d
inflammatory pain;
e
anti-inflammatory and antihemorrhage;
f
anti-edematogenic. The anti-inflammatory potential was evaluated, in vitro, through the effects on some inflammatory mediators such as NF-κ B factor: nuclear factor-kappa B; LPS: lipo-polysaccharides; NO: nitric oxide; IL: interleukins; PGE2: prostaglandin-E2; TNF-α : tumor necrosis factor alpha; COX: cyclooxygenase; LOX: lipoxygenase
Achillea
A. millefolium L.
Aerial parts
Apigenin, luteolin, and its glycosidic derivatives, chlorogenic and caffeic acid
Ethanolic extract in olive and sunflower oil
Application of extracts on irritated skin by sodium lauryl sulphate
[19 ]
Acmella
A. oleraceae (L.) R. K. Jansen
Aerial parts
Hydrocarbons, monoterpenes, sesquiterpenes, and arylpropanoides (genus)
Ethanolic extract
Ear edema (0.5; 2.5; 5 mg/mL/ear) Oral (300 – 1200 mg/kg)
[20 ]
A. pilosa R. K. Jansen
Stem
Rosmarinic acid and caffeic acid
Ethanolic extract
Carrageenan-induced paw edema
[21 ]
Ageratina
A. pichinchensis (Kunt) R. M. King & H. Rob.
Aerial Parts
7-O-(β -D-glucopyranosyl)-galactin
Aqueous Extract
Paw edema induced by carrageenan
[22 ]
Ageratuam
A. fastigiatum (Gardner) R. M. King & H. Rob.
Aerial parts (leaves and inflorescences)
α -pinene, limonene, trans-caryophyllene, α -humulene, caryophyllene oxide, 1,2-humulene-epoxide, 1,6- humulanodien-3-ol, and α -cadinol
Essential oil
Viability of peripheral blood leukocytes and effect on cytokine production (5 × 10−3 ; 10−2 ; 2.5 × 102 µL/mL) after exposure to different concentrations of essential oil and in vitro effect of essential oil on the production of cytokines by human lymphocytes
[23 ]
Aucklandia
A. lappa DC.
–
Terpenes, anthraquinones, MeOH extract alkaloids, flavonoids
Induced neutrophil cytokine inhibition (MeOH ext. 0.1 mg/mL) and acute and chronic inflammation-induced paw edema and peritonitis (EtOH Ext. 50 – 200 mg/kg)
[24 ]
Arctium
A. lappa L.
Leaves
Sesquiterpenolactones
Onopordopicrin- enriched fraction
Model of colitis induced by 2,4,6-trinitrobenzene sulfonic acid
[25 ]
A. minus (Hill) Bernh
Leaves
Phenolic compounds expressed in terms of gallic acid
Aqueous and ethanolic extract
Carrageenan-induced paw edema
[26 ]
Arnica
Arnica montana L.
Flowers
Quercetin, rutin, and apigenin and chlorogenic acid. Total sugar and total uronic acids contents
Polyphenolic and polysaccharide extract and liposomal formulations
Cell morphology model and pro-inflammatory cytokines Production
[27 ]
Flower heads
Sesquiterpenelactones, helenalin, and derivatives
Different dyes and gel
Inhibition of MMP1 and MMP13 mRNA and consequent inhibition of NF-κ B
[28 ]
Artemisia
A. herba-alba Asso
Aerial Parts
Hispidulin and cirsilineol
Ethanolic extract (percolation)
Paw edema (100; 200 and 400 mg/Kg p. o.)
[29 ]
A. judaica L.
Aerial Parts
Monoterpenes (piperitone, camphor, and ethyl cinnamate)
Essential oil
NO inhibition in macrophage culture induced by (LPS)
[30 ]
A. pallens Wall. Ex DC.
Aerial Parts
Sesquiterpenolactones
Methanolic extract
Acetaminophen-induced nephrotic model and hepatotoxicity
[31 ]
Atractylodes
A. lancea (Thunb.) DC.
Rhizomes
β- eudesmol
Atractylochromene, quinone, β -eudesmole atractylon
Inhibition of 5-LOX and COX-1
[32 ]
Baccharis
B. incarum (Wedd.) Perkins, B. boliviensis (Wedd.) Cabrera
a
Aerial parts (std 0.1 – 0.8 mg/mL flavonoids and flavoinois)
Flavonoids and terpenoids
Ethanolic extracts
Inhibition of COX-1, COX-2, and PGE2
[33 ]
B. uncinella DC.
Aerial parts
Non-glycosylated flavonoids, triterpenes, and phenolic derivatives
Organic fractions of ethanolic extract
Phospholipase A2-induced paw edema of rattlesnake and carrageenan
[34 ]
B. trimera (Less.) DC.
Aerial parts
Flavonoids, tannins, saponins, alkaloids, isoprenoids
Aqueous extract (infusion), ethanolic fraction, and aqueous fraction
Carrageenan-induced paw edema
[35 ]
Bidens
B. tripartita L.
Aerial parts
Catechin, chlorogenic ac., caffeic acid, luteolin-7-O-glucoside, chicoric acid, luteolin, Hydroxycinnamic acid, luteolin glucoside, polyacetylenes
Hydroalcoholic extract
Paw edema (4, 10, and 20 ml/Kg)
[36 ]
Cream containing 2.5% extract
Psoriasis
B. pilosa L.
Whole Plant
Phenylpropanoids, sesquiterpenes, phytosterols, chalcones and terpenes, poilacetylenes and flavonoids
ECOBIDENS® glycolic extract formulated with POLOXAMER
Mucositis induced in rats with 5-fluorouracil (75; 100 and 125 mg/Kg)
[37 ]
B. pilosa L.
Glycolic extract
Phenylpropanoids, sesquiterpenes, phytosterols, chalcones and terpenes, poliacetylenes and flavonoids
FITOPROT mucoadhesive formulation
Mucositis induced in rats with 5-fluorouracil
[38 ]
Calendula
C. officinalis L.
Flowers
Triterpenoid (esters of faradiol-3-myristic acid, faradiol-3-palmitic acid, and 4-taraxasterol)
Ethyl acetate soluble fraction of the methanol extract
Ear inflammation induced by 12-otetradecanoyl phorbol-13-acetate (TPA)
[39 ]
Esters of faradiol-myristic acid, faradiol-palmitic acid, and Ψ-taraxasterol
Dichloromethane extract
Croton oil-induced edema
Cream containing calendula extract
Dextran and burn edemas
Carthamus
C. tinctorius L. (C. flos–the dried floret)
Safflower
Ginkgolide B, saffloquinoside A
Safflor yellow (25 and 50 mg/kg, intraperitoneal)
Rats of pulmonary fibrosis induced by bleomycin (in vivo )
[40 ]
Centaurea
C. tchihatcheffii Fisch. & C. A. Mey.
Flowers, leaves, and stems
Sesquiterpenlactones
Ethanol extracts
Paw edema induced with carrageenan and PGE2 and ear edema induced with 12-O-tetradecanoyl-13-acetate (TPA)
[41 ]
C. ainetensis Boiss.
Aerial parts
Guaianolide (salograviolide A)
Methanol extract
Inhibited endotoxin (ET)-induced IL-6 levels in SCp2 mammary epithelial cells model and decreased the levels of IL-1-induced COX enzyme levels in intestinal epithelial cells model.
[42 ]
Chiliotrichum
C. diffusum (G. Forst.) Kuntze
Flowers
Chlorogenic acid, caffeic acid, hyperoside, isoquercetrine, quercitrin, afzelin, quercetin, apigenin, and kaempferol
Aqueous extract (Decoct)
Paw edema (30 and 100 mg/Kg)
[43 ]
Chromolaena
C. odorata (L.) R. M. King & H. Rob.
Aerial Parts
Essential oils, flavonoids
MeOH extract (fatty acid, coriolic acid, methyl ester, α , 15,16-didehydrocorp, alkali, and 15,16-didehydrochloride, methyl ester, linoleamide, linolenamide
Inhibition of NO production and NF-κ B activity in LPS-stimulated macrophage culture
[44 ]
Leaves
Scutellarin, tetramethyl ether
Dichloromethane extract
Inhibition of NF-κ B activity (10 µg/mL)
[45 ]
Conocliniopsis
C.prasiifolia (DC.) R. M. King & H. Rob.
Leaves
Sesquiterpene lactones, coumarins, flavonoids
Ethanolic extract
LPS-induced neutrophil degranulation (0.1 – 50 µg/mL)
[46 ]
Dichrocephala
D. integrifolia (L. f.) Kuntze
Whole plant
Portulide glucoside A and dichroditerpene A (diterpenes) 14-acetoxy-9-epi-britanlin A (sesquiterpene)
Extracts soluble in EtOAc and n-BuOH from partition of the MeOH: H2 O extract
Antineutrophilic inflammatory activities against superoxide anion generation and elastase release assay
[47 ]
Echinaceae
E. purpurea (L.) Moench
Leaves and roots
Germacrene D, naphthalene, caryophyllene oxide, α -felandren, and α -cadinol
Essential oil
Carrageenan-induced paw edema
[48 ]
Echinops
E. spinosus L.
Rhizome
–
Aqueous, ethanol, and chloroform extracts
Carrageenan-induced rat sub-plantar edema and arachidonic acid-induced mouse ear edema models
[49 ]
Leaves
5,7-dihydroxy-8,4′-dimethoxy-flavanone-5-O -α -L-rhamnopyranosyl-7-O -β -D-arabinopyranosyl-(1 → 4)-O -β -D-glucopyranoside
Methanolic extracts
Carragenan-induced hind paw edema method
Whole plant
–
Ethanol extracts
Anti-inflammatory activity induced by carrageenan, formaldehyde-induced acute and chronic arthritis, and adjuvant-induced acute and chronic arthritis
Eclipta
E. prostrata (L.) L.
b
Whole plants
Wedelolactone, demethylwedelolactone, oroboside
Methanol extract
Asthma induced with OVA model (i. p.)
[50 ]
Leaves
Steroids, triterpenoids, flavanoids, reducing sugar, tannins and saponins
Methanol extract
Carrageenan and egg white-induced hind paw edema in rats
[51 ]
Egletes
E. viscosa (L.) Less.
Seeds
Flavonoids (ternatin), saponins, catechins, xanthones, flavonoids
Aqueous extract
Formalin assay
[52 ]
Emilia
E. sochifolia (L.) DC. ex DC.
Aerial parts
Quecetrin; kaemferol C-glycoside derivative; chlorophyll; carrotenoid derivatives; triterpenoids; and phenolic acids–caffeic acid derivatives
Methanol/methylene chloride extract
Levels of IL-1β and TNF-α after an intraperitoneal lipopolysaccharide challenge and TNF-α and inducible (iNO) production by LPS-stimulated bone marrow-derived macrophages (BMMDM) models
[53 ]
Eremanthus
E. erythropappus (DC.) MacLeisch
Branch
Sesquiterpenoids and sesquiterpenic lactones
Ethanolic extract
Paw edema (100 and 200 mg/Kg)
[54 ]
Erigeron
E. annuus (L.) Pers.
Roots
Sesquiterpenoids, diterpenoid, sterols, and triterpenoids
Methanol extract
NO Production, carrageenan-induced paw edema and carrageenan-induced acute inflammation
[55 ]
Eupatorium
E. perfoliatum L.
Aerial parts
Polysaccharides, sesquiterpene lactones, and flavonoids
MeOH-, EtOH-, and DCM extracts and fractions
LPS-stimulated cells by NO/iNOS quantification, gene array, real-time PCR, and ELISA.
[56 ]
Felicia
F. muricata Thunb. (Nees)
Leaves
Alkaloids, flavonoids, tannins, saponins, and phenolics
Aqueous extract
Paw edema induced by carrageenan and egg albumin
[57 ]
Galinsoga
G. parviflora Cav.
Aerial parts
Flavonoids, aromatic esters, caffeic acid derivatives, diterpenoids, and phenolic acid derivatives.
Methanol, hexane extracts, and H2 O fractions
COX-1 assay and (5-LOX)
[58 ]
Gochnatia
G. polymorpha (Less.) Cabrera
Trunk bark
11,13-dihydrozaluzanin C
Ethanol extract, ethyl acetate and other fractions, and the isolated compounds bauerenyl acetate and 11,13-dihydrozaluzanin C
Paw edema and carrageenan-induced air pouch inflammation models
[59 ]
G. pulchra Cabrera
Aerial Parts
Sesquiterpene lactone, dimeric guaianolide, bisabolines; diterpenes, triterpenes, coumarin
Alcoholic extr. and genkwanine, scutelarine, apigenin, 3,5 dicapheoilquinic
Paw edema/pleurisy (50; 100 e 500 µg/Kg)
[60 ]
Gynura
G. procumbens (Lour.) Merr.
Aerial parts
–
Ethyl acetate
Ear inflammation inhibition
[61 ]
Aerial parts
Essential oils, titerpenes/ steroid, bitter principles
Hexane and toluene fractions of ethyl acetate extract
Ear inflammation inhibition Less inflammatory cells at granulation tissue
Leaves
Flavonoids/saponins
Ethanol
Increased in release of cytokine such as IL-2 and IFNγ
Helichrysum
H. graveolens (M.Bieb.) Sweet
c
Flowers
Apigenin
Methanol extract and n-hexane, CH2 Cl2 and n-butanol fractions
Wound-healing activity and inflammatory activity using the acetic acid induced increase in capillary permeability test are different assays
[62 ]
H. italicum (Roth) G.Don
Flowers
Gnaphaliol 9-O-propanoate and 5 known acetophenonones
Chloroform fraction of EtOH extract
Nitrite measurement in J774 macrophages
[63 ]
H. italicum subsp. microphyllum (Willd.) Nyman
Leaves and flower heads
Arzanol
Petroleum ether-ethyl acetate of acetone extract
Inhibition of NF-κ B activation, release of proinflammatory mediators: interleukins, TNF-α , and PGE2
[64 ]
Heliopsis
H. longipes (A.Gray) S. F. Blakea
Roots
Spilanthol
Enriched hexane extract
Freudʼs adjuvant-induced arthritis model (2; 6.6 e 20 mg/Kg p.o)
[65 ]
Root
Alkamides
Ethanolic extract
Production of TNFα and NO by activated RAW264.7 macrophage
[66 ]
Heterotheca
H.subaxillaris var. latifolia (Buckley) Gandhi & R. D. Thomas
Aerial Parts
Santin, pectolinaringenin; 3,6-dimethyl-5,7,4-trihidroxiflavone; and hispidulin
Petroleum ether, dichloromethane, and methanol extracts
Ear and paw edema
[67 ]
Inula
I. cuspidata (Wall. ex DC.) C. B. Clarke
Stem and root
Alkaloids, flavonoids, triterpenoids, steroids, tannins, and phenolic compounds
Chloroform and methanol extracts
Carrageenan-induced paw edema model
[68 ]
I. japonica Thunb.
–
Sesquiterpene lactones
–
Inhibition of UBcH5 (suppression of the TNF-α and NF-κ B gene (2.5 – 10 µM)
[69 ]
Jasonia
J. glutinosa (L.) DC.
Plant
Sesquiterpenes (lucinone, glutinone, epi-kutdtriol, and kutdtriol)
Aqueous acetone solution, aqueous methanol solution, benzene or hydrodistillation
COX-1 inhibiting a decreasing the production of PGE2 in cells models
[70 ]
Jungia
J. sellowii Less.
Leaves
Succinic acid and lactic acid
Ethanol/water extract and n-hexane, dichloromethan, ethyl acetate and n-butanol fractions, and aqueous fraction
Pleurisy induced by carrageenan
[71 ]
Lychnophora
L. passerina (Mart. ex DC.) Gardner
Aerial Parts
Triterpenoids, sesquiterpenoids, steroids, and flavonoids
Ethanolic extract in lanolin-vaseline base
Inhibition of NO production, TNF-α , and stimulation of IL-10. Carrageenan-induced paw edema
[72 ]
Sesquiterpene lactone (goiasenzolide)
Ethanolic extract
Carrageenan-induced paw edema
[73 ]
L. salicifolia Mart.
Leaves
Chlorogenic acid
(Butanol fraction of MeOH/water extract)
Inhibition of the production of interleukin, TNF-α and PGE-2 in stimulated neutrophils (50; 100 e 400 µM)
[74 ]
L. trichocarpha (Spreng.) Spreng. ex Sch.Bipa
Aerial parts
Luteolin, apigenin, Sesquiterpenolactone (lichnofolide and eremantholide C), lupeol
Ethanolic extract and fraction in ethyl acetate
Paw edema induced by urate monosodium crystal
[75 ]
Matricaria
M. chamomilla L.
d
–
α -bisabolol, bisabolol oxide A, and guaiazulene
Ethanolic extract
Formalin test
[76 ]
Mikania
M. cordata (Burm.f.) B. L. Rob.
Aerial Parts
Betulinic acid derivative
Chloroform extract
Paw edema 100 mg/Kg b.w
[77 ]
Mikanine, friedelin, kaurenoic acid, butynyloxy and benzyloxy, stigmasterol and sitosterol
Essential oil and chloroform and ethyl acetate extract
Paw edema (200; 400; 800 mg/Kg b.w)
[78 ]
M. glomerata var. glomerata.e
Leaves
Terpenes, essential oils, di and sesquiterpenolactone, flavonoids, stigmasterol, Alcohols, acids, esters, aldehydes, organic esters, and steroids
Hydroalcoholic Extract
Intra-dermal injection in rats infected with Bothrops venom (3.2; 6.4; 12.8 µg/mL)
[79 ]
M. lindleyana DC.
Aerial Parts
Stigmasterol and esters of stigmasterol, fatty acids
Methanolic extract
Carrageenan-induced peritonitis (0.5; 1.0 e 2.0 g/Kg)
[80 ]
M. micrantha Kunth
Stem with leaves, and inflorescences with seeds
Linalool and a-pinene
Hexane, ethyl acetate, and methanol extracts
Mouse ear edema assay induced with TPA (12-O-tetradecanoyl-phorbol-13-acetate)
[81 ]
Moussonia
M. deppeana (Schltdl. & Cham.) Klotzsch ex Hanst.
CicatrisanTM /GastricusTM , GastinolTM , and GastrovitaTM
Sitosterol and stigmasterol, ursolic oleanolic, caffeic and chlorogenic acid
EtOH extracts of three dietary supplements
TPA and by carrageenan murine models
[82 ]
Pseudobrickellia
P. brasiliensis (Spreng.) R. M. King & H. Rob.
Leaves
Quininic acid and derivatives, 5-caffeoylquinic acid; 3,5-dicetheoylchinic acid; flavonoids, luteolin and luteolin dihexoside
Aqueous extract, ethanolic and ethyl acetate
Inhibition of pro-inflammatory action in mononuclear cell culture (12.5 – 100 µg/mL extrato)
[83 ]
Santolina
Santolina spp.
–
Monoterpenes and sesquiterpenes, flavonoids and coumarins
Metanol, chloroform, hexane, dichloromethane, ethyl acetate, and petroleum ether extracts
Croton oil-induced dermatitis in mouse ears; PLA2-induced mouse paw edema; carrageenan paw edema in rats; inhibition of PLA1; adjuvant carrageenan-induced inflammation, ACII, model using Wistar male rats; ionophore-stimulated mouse peritoneal macrophages; NF-κ B, IL-6, IL-8, TNF-α , PGE2
[84 ]
Saussurea
S.heteromalla (D.Don) Hand.-Mazz.
Whole plant
Chlorojanerin, a guaianolide type of sesquiterpene lactone
Chlorojanerin (ethyl acetate fraction from dichloromethane : methanol extract)
TNF- and IL-6 inhibition in LPS stimulated THP-1 cells and in synovial cells from a patient with rheumatoid arthritis
[85 ]
Scorzonera
S. latifolia (Fisch. & C. A. Mey.) DC. and Scorzonera mollis subsp. szowitzii (DC.) D. F. Chamb.
Aerial parts
Chlorogenic acid
Methanol-water extracts
In vivo wound healing activity
[86 ]
Senecio
S. brasiliensis (Spreng.) Less.
Flowers
Alkaloids senecionine, integerrimine, and senecionine N-oxide and mixture of 1,4-, 3,4-, 3,5- and 4,5-dicaffeoylquinic acids
Hexane, CH2 Cl2 , and ethyl acetate fractions from ethanol (96%) extract Alkaloid fraction from ethanol (96%) extract
Pleurisy induced by carrageenan
[87 ]
Smallanthus
S. sonchifolius (Poepp.) H. Rob.
Leaves
Chlorogenic acid, sesquiterpene lactones
Aqueous, polar extract (MeOH) and leaf “washed” extract (acetone)
Ear edema (0.125 – 0.5 mg/ear) and inhibition of neutrophil migration (0.25 – 1.0 µg/mL)
[88 ]
Solidago
S. chilensis Meyen
Rhizomes, leaves and inflorescences
Labdane diterpene solidagenone
Aqueous extracts
Mouse model of pleurisy induced by carrageenan
[89 ]
Rhizome
Chlorogenic acid and caffeic acid
Aqueous extract, and its butanolic and aqueous fractions
Mouse model of the air pouch induced by carrageenan
[90 ]
Aerial parts
Caffeoylquinic acid derivatives and the flavonoid rutin
Hydroalcoholic extract
Ear edema model induced by topical application of the chloroform fraction of latex-extract from Euphorbia milii .
[91 ]
Aerial parts
Rutin and phenylpropanoids, monocaffeoylquinic acid (chlorogenic acid) and dicaffeoylquinic acid (ethanolic extract)
Gel cream containing a 5% glycolic plant extract
Clinical trial for the treatment of tendonitis of flexor and extensor tendons of wrist and hand
[94 ]
Inflorescences
Quercetin, kaempferol, solidagenone, isoquercitrin, quercitrin, afzelin, chlorogenic acid, nicotiflorin, and isoquercitrin
Ether-ethanol extract
Inhibition of NO in LPS-induced macrophage culture
[95 ]
S. virgaurea L.
Plant
Quercetin, rutin, and kaempferol; salicylic acid derivatives; triterpene saponins, tannins, essential oils
Standardized extract in routine ≥ 0.2 mg/mL)
Inhibition and modulation of interleukin and TNF-α of LPS-stimulated fibroblasts (0.02 e 0,1%)
[96 ]
S. virgaurea L.
Aerial parts
3,5-O-Dicaffeoylquinic acid, 3,4-O-dicaffeoylquinic acid, 3,4,5-O-tricaffeoylquinic acid and 4,5-O-dicaffeoylquinic acid
Phenolic-rich fraction from ethanol : water 30 : 70 extract
Carrageenan-induced rat paw edema model
[97 ]
Sonchus
S. oleraceus (L.) L.
Aerial parts
Flavonoids and sesquiterpenes
Hydroethanolic extract
Carrageenan-induced paw edema, peritonitis, and febrile response induced by lipopolysaccharide tests
[98 ]
Sphagneticola
S. trilobata (L.) Pruski
Aerial Parts
Kaureoic acid, phenylpropanoids, and triterpene saponins
Semi-solid containing 1% dry extract standardized in kaurenoic acid
Ear edema induced by chrotonic oil, arachidonic acid, or TPA
[99 ]
Stems and roots
Kaurenoic acid
Creams containing kaurenoic acid, isolated from the acetonic extract
Croton oil-induced ear edema method
[100 ]
Silybum
S. marianum (L.) Gaertn.
Fruits and seeds
Silymarin
Silymarin
UVB-induced edema and hyperplastic response in SKH-1 hairless mouse skin model
[101 ]
S. marianum (L.) Gaertn.
c
Seed
Silibinin
Silibinin 0.2% in hydrogel
Model of wound incision in rat
[102 ]
Tagetes
T. minuta L.
Leaves
Dihydrotagetone, E-ocimene, tagetone, cis-β -ocimene, z-ocimene, limonene, epoxyocimene
Essential oil
NADH oxidase and, NO synthase measures, TNF-α mRNA expression in LPS stimulated macrophages using real time PCR
[103 ]
T. erecta L.
Leaves
Xanthophylls, lutein, carotenoids
α -and β -carotene, lycopene, and retinoids
Chloroform, methanol, and ether extracts
Acetic acid-induced writhing in mice and carrageenan-induced paw edema in rats
[104 ]
Tanacetum
T. argenteum (Lam.) Willd.
Plant parts
Sesquiterpene lactones (Parthenolide) and pyrethrins
n-Hexane, ethyl acetate, and methanolic extracts
iNOS and NF-κ B inhibition tests on RAW264.7 and HeLa cells
[105 ]
T. vulgare L.
a
–
Myrtenol
Essential oils
Paw edema and articular incapacitation
[106 ]
Tanacetum spp.
Aerial parts
Parthenolide
Chloroform and metanol : water extracts
Wound-healing activity/inhibition of acetic acid-induced increase in capillary permeability
[107 ]
Taraxacum
Taraxacum spp.
a
Leaves and roots
Sesquiterpenes, saponins, flavonoids, and sugars, terpenes (mainly lupeol, taraxasterol and luteolin)
Extracts
Influences certain inflammatory mediators in Leukocytes (in vitro ). Inhibits the production of inflammatory cytokines in rats, mice. Anti- inflammatory activity in disease in humans (in vivo ).
[108 ]
Tithonia
T. diversifolia (Hemsl.) A. Gray
f
Leaves
Chlorogenic acids and sesquiterpene lactones, flavonoids
Extract of leaf washing, infusion and polar extract
Carrageenan-induced edema and Croton-oil-induced ear edema and assessment of neutrophil migration
[109 ]
T. diversifolia (Hemsl.) A. Gray
Leaves
Terpenoids, sesquiterpene lactones, dicafeoylquinic acid derivatives, flavonoids
Tagitinin A, C, and F
Inhibition of the production of ILs and TNF-α in culture of neutrophils induced by LPS
[110 ]
Tragopogon
T. graminifolius DC.
Aerial Parts
Luteolin, vitexin, isovitexin, vicentin-1,2 and orientin, phenolic compounds
Eucerine cream containing ethanolic extract (5 – 10%)
Heat-induced wound healing test
[111 ]
Tripleurospermum
T. parviflorum (Willd.) Pobed. and T. tenuifolium (Kit.) Freyn ex Freyn
Aerial parts
Linoleic acid and palmitic acid (oil)
n -Hex, ethyl acetate, MeOH and aqueous extracts
Carrageenan-, and serotonin-induced hind paw edema and acetic acid-induced increase in capillary permeability models
[112 ]
Tussilago
T. farfara L.
Leaves
Sesquiterpenoids
CH2 Cl2 and MeOH extracts, CH2 Cl2 extract without chlorophyll, MeOH extract, and detannified methanol extract
PPARs activation and on NF-κ B Inhibition, LPS- or TNF-α -induced downregulation of interleukine-8 (IL-8) and E-selectin mRNA
[113 ]
Vernonia
V. condensata Baker
Leaves
Dicafeoylquinic acid, apigenin, luteolin, chlorogenic acid
Fraction in ethyl acetate from ethanolic extract
Inhibition of cytokines and NO and TNF-α in RAW 264.7 cells induced by LPS (10 e 20 µg/mL)
[114 ]
V. polyanthes Less.
f
Branches
di-O- (E) -cafeoylquinic acid, luteolin, quercetin, protocatechinic acid, quercetin-3-O-β -glucoside, apigenin, and isohamnetin
Ethanolic extract and fraction in ethyl acetate, derived from partitioning
Ear edema induced by Croton oil, arachidonic acid, and phenol
[115 ]
V. scorpioides (Lam.) Pers.
Leaves and flowers
Flavonoids, steroids, and polysaccharides
Ethanolic extract of leaves and flowers
Acute and chronic ear edema
[116 ]
Xanthium
X. spinosum L.
Roots
Ziniolide (12,8-guaianolide sesquiterpene lactone)
MeOH and n-hexane, CHCl3 , and CHCl3/MeOH (9 : 1) extracts, hydroalcoholic and n-hexane fractions, ziniolide
Determination of 5-LOX, COX-1, 12-, and 15-LOX activities. Determination of the activation of the NF-κ B
[117 ]
X. strumarium L.
Aerial parts
Caffeic acid, reversatrol
Methanolic extract
LPS treated macrophages and an HCl/EtOH-induced mouse model of gastritis
[118 ]
According to Chagas-Paula et al. [18 ], some Compositae species act as potent inhibitors through the mechanism of dual inhibition of cyclooxygenase-1 (COX-1) and 5-lipoxygenase (5-LOX). However, other mechanisms of action for the anti-inflammatory potential of this family are discussed.
Articles strictly related to ethnobotany were evaluated and used as important reference sources even though they did not reference experimental conditions, since most of them only mentioned the popular use of the species.
The most cited species in the obtained literature for anti-inflammatory activity or anti-inflammatory potential were the different types of arnica (Solidago, Lychnophora, Tithonia, Chromolaena, Heterotheca ). Other species mentioned in the scientific literature for anti-inflammatory activity were yarrow (Achillea millefolium ), chamomile (Matricaria chamomilla ), artemisia (Artemisia spp.), baccharis (Baccharis spp.), vernonia (Vernonia spp.), burdock (Arctium lappa ), guaco (Mikania spp.), Echinacea (Echinacea purpurea ), and Beggar-ticks (Bidens pilosa ).
Thus, despite the vast number of species from the Compositae family reported against inflammatory processes and the traditional use of some, we highlight only those with bibliographic references that confirm their anti-inflammatory activity as important species with technological potential: A. millefolium, A. lappa, Artemisia spp., Baccharis spp., Bidens pilosa, E. purpurea, Vernonia spp., and 5 synonyms of arnica (Chromolaena odorata, Heterotheca subaxillaris, Lychnophora spp., Solidago chilensis, and Tithonia diversifolia ) ([Fig. 2 ]).
Fig. 2 Compositae species with anti-inflammatory activity with greater technological.
Achillea millefolium
A. millefolium , popularly known as yarrow, is considered one of the most widely used medicinal plants in the world. Yarrow has been used for thousands of years to heal wounds and cure infectious diseases. The literature describes it as an anti-hemorrhagic and anti-inflammatory, and it is also used for digestive and respiratory problems. It is still referred to as a panacea [119 ]. It appears in official Brazilian compendia, as in the FFFB and its Supplement, for internal use, through the oral administration of infused or percolated and tincture from its aerial parts, with anti-inflammatory activity, among others [9 ], [120 ].
Tadic et al. [19 ] demonstrated the anti-inflammatory potential of A. millefolium extracts in an irritated human skin model. They attributed the topical anti-inflammatory action to its composition, which includes luteolin and its glycosidic derivatives, apigenin and its derivatives glycosides, and phenolic acids, such as caffeic and chlorogenic acids. Some metabolite structures found in the main species are shown in [Fig. 3 ].
Fig. 3 Structures isolated from some Compositae species.
According to Bessada et al. [121 ], the major components found in A. millefollium are flavonoids, such as apigenin (1) and quercetin (2), and phenolic acids, such as caffeoylquinic acid. The phytochemical profile of A. millefolium also presents relevant contents of organic acids (oxalic, quinic, and citric), fatty acids (linoleic, palmitic, among others), and tocopherols (especially γ -tocopherol).
Arctium lappa
A. lappa is popularly known as “burdock” and is used in folk medicine as a diuretic, depurative, digestive stimulant, and anti-inflammatory. It has been used therapeutically for years in Europe, North America, and Asia [122 ], being on the list of phytotherapeutic monographs for traditional use in the European community [123 ]. In Brazil, burdock has been indicated for internal use through its decoction and tincture based on its roots as antidyspeptic, diuretic, and anti-inflammatory, as well as for urinary disorders and inappetence. In addition, scientific studies have proven its anti-ulcerogenic, antioxidant, antiallergic, and anti-inflammatory properties by different models of in vivo activity. De Almeida et al. [25 ] investigated the effects of a fraction enriched in onopordopicrin, a sesquiterpene lactone, using a model of colitis induced by
2,4,6-trinitrobenzenesulfonic acid, to study and elucidate the involved mechanisms. The animals treated with the enriched fraction had a significant reduction in the inflammation parameters evaluated, such as myeloperoxidase (MPO) activity, TNF-α levels, edema, as well as morphological changes associated with increased mucus secretion. The decrease in neutrophil infiltration and cytokine levels was also detected. In addition, COX-2 expression decreased in the animals treated with the enriched fraction, confirming its popular use for inflammatory bowel diseases.
The main components isolated from this species are tannins, arctigenin (3), arctiin (4), beta-eudesmol, caffeic acid (5), chlorogenic acid, inulin, trachelogenin, 4-sitosterol-β -D-glucopyranoside, lappaol, and diarctigenin [122 ].
Artemisia spp.
The genus Artemisia comprises 481 species with accepted nomenclatures [124 ]. These include the species A. herba-alba, A. judaica , and A. pallens , with scientific evidence of anti-inflammatory activity or potential through in vivo and in vitro tests, respectively, that classify it as an important species with technological potential.
A. herba-alba , known in Egypt as “Sheh”, is a well-known medicinal plant used in traditional Middle Eastern medicine to treat various diseases. This species is rich in flavonoids like hispidulin and cirsilineol, with anti-inflammatory action attributed to these components. Jaleel et al. [29 ] evaluated the anti-inflammatory activity of A. herba-alba through the reduction of carrageenan-induced paw edema, using ethanolic extract of its aerial parts.
A. pallens is a medicinal aromatic species native to Southern India, and the chemical composition of its oils has been described by some researchers. Pharmacological activities include, among others, antipyretic, analgesic, antidiabetic, antimicrobial, antioxidant, and anti-inflammatory. To prove the anti-inflammatory activity of A. pallens , Honmore et al. [31 ] evaluated the inhibition of NO production, in vivo , among other biochemical and molecular parameters in a nephrotic model and acetaminophen-induced hepatotoxicity in rats, where methanolic extract of its aerial parts presented good results. Analyzes reported by quantitative structure activity relationship (QSAR) demonstrated the presence of sesquiterpenolactones in A. pallens , which are indicated as responsible for the hepatoprotective action.
Like other Artemisias, A. judaica is also found in several traditional preparations to treat inflammation and other infections caused by fungi, bacteria, and viruses, being a widely used species in Jordanian folk medicine. Abu-Darwish et al. [30 ] demonstrated anti-inflammatory potential of its oil by in vitro NO inhibition assay in LPS-induced macrophages cultured, where the oil significantly inhibited their production. Among the major constituents found in the oil composition, the monoterpenes were prominent, in addition to piperitone, camphor, and ethyl cinnamate.
Baccharis spp.
Baccharis is an important genus of the Compositae family and comprises approximately 400 species, where about 120 occur in southern and southeastern Brazil. Several of its species are used in folk medicine as an antibiotic, antiseptic, and for wound healing. In South America, it is widely used to treat inflammation, headaches, diabetes, and hepatobiliary disorders. Baccharis spp. basically contains diterpenoids, triterpenoids, flavonoids, and chromenes [34 ].
Alberto et al. [33 ] demonstrated the anti-inflammatory potential of Baccharis incarum and Baccharis boliviensis . An immunoassay technique was employed to evaluate the percentage of inhibition of PGE2 production by inhibition of COX-1 and COX-2 by ethanolic extracts of its aerial parts, where B. incarum presented better results. Their chemical compositions showed high concentrations of phenolic compounds, among them flavone and flavanone.
Zalewski et al. [34 ] investigated the anti-inflammatory activity of dichloromethane (CH2 Cl2 ) and ethyl acetate (AcOEt) fractions as well as isolated substances from ethanolic extract of B. uncinella . By the phospholipase A2-induced paw edema method of previously incubated and not incubated Crotalus durissus terrificus with the isolated fractions and substances or carrageenan, the capacity of Baccharis uncinella to reduce edema was determined. Chromatographic and spectroscopic methods were used to determine the presence of non-glycosylated flavonoids and triterpenes in the CH2 Cl2 fraction (oleanolic and ursolic acids and pectolinaringenin) and the presence of phenolic derivatives in the AcOEt fraction, caffeic, and ferulic acids (6), identified as responsible for the anti-inflammatory action of the fractions.
Nogueira et al. [35 ] also identified the anti-inflammatory activity of Baccharis trimera through the reduction of paw edema induced by carrageenan, when using aqueous extract and aqueous and ethanolic fractions, in which all presented significant results. The chemical composition of the species is mostly flavonoids but also includes tannins, saponins, alkaloids, and isoprenoids. The FFFB and its supplement also present this species as infusions and tincture for internal use as antidyspeptic [9 ], [120 ].
Bidens pilosa
Bidens pilosa , popularly known as Beggar-ticks, is a native species to South America and found in most tropical and subtropical countries, as well as in some regions of Europe [125 ], [126 ].
Several studies have described the popular use of the species, including jaundice, malaria, inflammatory processes, asthma, and wound healing. Polyacetylenes and flavonoids (including chalcones and auronas) are among its chemical constituents [126 ].
One of the main uses found for Beggar-ticks was to treat intestinal mucositis caused by chemotherapeutic treatment of certain patients. De Ávila et al. [37 ] proposed a glycolic extract formulation of B. pilosa incorporated in polaxamer gel to treat mucositis in mice induced by 5-fluoruoracil (5-FU). In these experiments, the animals were treated by gavage with the mucoadhesive product for 6 d, while on the fourth and the sixth d, they were treated with 5-FU. On the seventh d, the animals were euthanized for histomorphometric analysis. As expected, animals treated only with 5-FU showed marked weight loss, reduction of intestinal villi, edema, inflammatory infiltrates, and intestinal vacuolization. On the other hand, the animals treated with the B. pilosa -based formulation attenuated the clinical and pathological changes, protecting the intestinal cells from cell death, regulating lipoperoxidation, and inflammatory
infiltration.
The same research group subsequently developed and patented a mucoadhesive formulation called FITOPROT, containing B. pilosa and other extracts with action against 5-FU induced cellular toxicity using an in vitro model of oral mucositis, where the FITOPROT-treated cells demonstrated a decrease in the pro-cytokine levels (IL-1β , IL-6 and IL-8) among other actions, which were responsible for the restoration of cellular capacity [38 ].
Chromolaena odorata
Chromolaena odorata , also called Eupatorium odoratum , has been popularly used as a poultice to stop bleeding or as an anti-inflammatory. Studies have demonstrated the presence of essential oils, alkaloids, and flavonoids [44 ].
Hanh et al. [44 ] demonstrated the anti-inflammatory potential of C. odorata through the inhibition of NO and NF-κ B in culture of macrophages stimulated by LPS against isolated substances. The organic fraction (CH2 Cl2 ) of the partition of the methanolic extract in water from its aerial parts was chromatographed. Six fatty acids were identified: (S)-coriolic acid, (S)-crocylic methyl ester, (S)-15,16-didehydroxychoriolic acid, (S)-15,16-didehydroxychoriolic acid methyl ester, linoleamide, linolenamide, where the latter was more effective at inhibiting NO production when incubated with the stimulated cell culture. Other nonconclusive studies demonstrate the modulating activity of C. odorata in COX [127 ]. Tran et al. [45 ] studied dichloromethane extract of C. odorata leaves and demonstrated the inhibition of NF-κ B using TNF-α
stimulated cells.
Echinacea purpurea
Echinacea purpurea , also known popularly as echinacea, is a species originally from the United States and has been used for centuries by Native Americans for combating various diseases [48 ]. This species appears in the list of monographs of traditional phytotherapy use of the European Medicines Agency (EMA), and it is in the MFFB for internal use to combat cold symptoms. Its main constituents are phenylpropanoids, polysaccharides, and sesquiterpenes [8 ].
Nyalambisa et al. [48 ] demonstrated the anti-inflammatory activity of the essential oil of its roots by the reduction of paw edema in mice. They also elucidated its chemical composition as mainly germacrene D, naphthalene, caryophyllene oxide, α -phellandrene (7), and α -cadinol (8).
Heterotheca subaxillaris
Heterotheca subaxillaris subsp. latifolia , widely distributed in the northwest and central regions of Argentina, is locally known as “camphor” due to its aromatic odor. In Mexico, it is used as an infusion of the entire plant to relieve menstrual pain. To study the possible relation of popular use with anti-inflammatory activity, Gorzalczany et al. [67 ] evaluated petroleum ether, dichloromethane, and methanol extracts from its aerial parts in carrageenan-induced paw edema model and 12-O-tetradecanoylforbol acetate-induced ear edema in mice. Dichloromethane extract produced significant activity in the ear test, reducing edema by 91%. Bio-guided fractionation found the presence of some major flavonoids: santin, pectolinaringenine, 3,6-dimethoxy-5,7,4-trihydroxyflavone, and hispidulin (9) in the active fractions.
Lychnophora spp.
Species of the genus Lychnophora are popularly known as Brazilian arnicas and native to the Brazilian savanna (Cerrado) [127 ]. Rich in sesquiterpene lactones, they are widely used in folk medicine as anti-inflammatory, for rheumatism, insect bites, among others.
De Souza et al. [75 ] and Ugoline et al. [73 ] evaluated Lychnophora trichocarpa and Lychnophora passerina, respectively, and observed their anti-inflammatory, anti-arthritis (due to the accumulation of uric acid in the joints), antihyperuricemic, and anti-edematogenic effects in reduction of paw edema induced by monosodium crystal urate or carrageenan.
De Souza et al. [75 ] evaluated the antihyperuricemic activity of the ethanolic extract, the ethyl acetate fraction, and substances isolated from the aerial parts of L. trichocarpa through diminution of urate levels caused by uricase and xanthine oxidase inhibition in the liver of hyperuricemic mice stimulated with potassium oxonate.
Ethanolic extract and ethyl acetate fraction significantly reduced urate levels, and the extract also inhibited the enzyme xanthine oxidase. The isolated substances–luteolin, apigenin, lupeol, lychnopholide, and eremantholide C–demonstrated antihyperuricemic effect. Luteolin also had the inhibitory effect of xanthine oxidase, but the other substances did not. In extracts, the ethyl acetate fraction and the substances lupeol, sitosterol, lychnopholide, eremantholide, luteolin, and apigenin were also able to reduce paw edema induced by monosodium urate crystals. These results demonstrated that both extract and some isolated substances are promising agents in the treatment of gouty arthritis because they have antihyperuricemic and anti-inflammatory effects.
Likewise, Ugoline et al. [73 ] demonstrated the antigouty, anti-inflammatory, and anti-arthritis activities for both the ethanol extract of Lychnophora passerina (collected in different seasons of the year) and for its main isolated substance, sesquiterpene lactone goyazensolide, through inhibition of the hepatic xanthine oxidase enzyme and by inhibition of carrageenan-induced paw edema. Although goyazensolide levels showed small variations depending on seasonality, the pharmacological effects were maintained, suggesting the participation of other substances in the antihyperuricemic and anti-inflammatory effects. The extracts of the plants collected in the summer, autumn, and spring had a greater hyperuricemic effect.
Capelari-Oliveira et al. [72 ] also studied the L. passerina species. They demonstrated the anti-inflammatory action of the ethanolic extract as well as methanol and ethyl acetate fractions of its aerial parts through the inhibition of NO, decrease of TNF-α levels, and induction of IL-10 in LPS-induced macrophages. The anti-edematogenic activity of the species was also confirmed when they incorporated ethanolic extract of their aerial parts in lanolin-vaseline base and successfully reduced paw edema in mice, similar to diclofenac gel.
Hebeda et al. [74 ] also demonstrated the chlorogenic acid action of Lychnophora salicifolia on the viability, locomotion, and adherence of neutrophils, as a participation in the inflammation mechanisms. Although chlorogenic acid did not decrease the levels of inflammatory mediators, levels of adhesion molecules in neutrophils culture stimulated by LPS form diminished, which may explain the anti-inflammatory effect of the species.
Solidago chilensis
Solidago chilensis is native to Chile, and predominant in South America, mainly in the South and Southeast regions of Brazil, where it is known as “arnica brasileira” [128 ], [129 ]. This species is very common in fields, along roadsides, and in abandoned crops. It has been widely used as an unofficial substitute for Arnica montana by the population as well as public and private companies [13 ] due to similar anti-inflammatory properties [130 ].
In Chile, this species is used to treat gastric and intestinal ulcers, and in other South American countries to treat secretions of the upper respiratory tract and as an anti-inflammatory [131 ]. In Brazilian popular medicine, S. chilensis is used as a diuretic, analgesic, and anti-inflammatory, in the treatment of burns, rheumatic diseases, among others. [128 ], [130 ].
Several references have pointed to anti-inflammatory activity through in vivo assays. Goulart et al. [89 ] demonstrated inhibition of leukocytes, neutrophils TNF-α , IL-1β , NO, among others, through the administration of aqueous extracts of their rhizomes, leaves, and inflorescences in a pleurisy model in mice. Similar results were obtained by Liz et al. and Gastaldo et al. [90 ], [92 ] when they tested aqueous and hydroalcoholic extracts, respectively, by applying open wound and air bag models in rats. Tamura et al. [91 ] demonstrated anti-edematogenic activity in an ear edema model both for topical and oral administration of hydroalcoholic extracts from its aerial parts, with inhibition of polymorphonuclear migration and decrease of circulating leukocytes adherence. Assini et al. [93 ] also demonstrated
anti-inflammatory activity of aqueous extract of roots through the formalin test in mice, when they observed a decrease in the number of lymphocytes in the inflammatory phase. Only one reference was found about an in vitro assay, where the ethanolic ether extract of its inflorescences decreased NO production in LPS-induced macrophage culture [95 ]. In addition, a reference was found using a semi-solid formulation (gel-cream) in a clinical study for cases of tendinitis in the flexor and extensor tendons of the wrist and hand [94 ].
According to Valverde et al. [13 ], S. chilensis flavonoids, such as quercetin, quercitrin (10), rutin (11), clerodanic and labdanic diterpenes (solidagenone (12), deoxysolidagenone, solidagolactone and other solidagolactol derivatives) are also described for this species.
Tithonia diversifolia
Tithonia diversifolia , native to the southeastern plains of Mexico and Central America but currently scattered throughout the world [109 ], is recognized worldwide for its antiparasitic, antimicrobial, and anti-inflammatory activities, among others. T. diversifolia , is a major source of bioactive molecules, among them phenolic compounds and terpenes (sesquiterpene lactones), such as tagitinin, which has been widely studied for its pharmacological properties, mainly related to the NF-κ B factor [110 ], although its action mechanism is still unknown.
To evaluate the tagitinins and their effects related to inactivation and neutrophil survival plus establish the mechanisms of inflammation, Abe et al. [110 ] investigated tagitinins A (13), C (14) and F (15) in purified and stimulated LPS neutrophils, where the enzymatic activity, apoptosis, and cytokinesterase secretion were determined after 18 h.
MPO activity was inhibited by tagitinin F, while apoptosis increased in the presence of tagitinin C. Tagitinins C, F, and A decreased production of IL-6, IL-8, and TNF-α . These results together demonstrated the anti-inflammatory potential of tagitinins, although tagitinin F was the only sesquiterpene lactone that decreased the secretion of neutrophil products, which consequently induced apoptosis.
Chagas-Paula et al. [109 ] also evaluated the anti-inflammatory and anti-edematogenic activity of T. diversifolia . Through the paw and ear edema assays and evaluation of neutrophil migration, these authors verified that polar extract and acetone washed leaf presented better results than nonsteroidal anti-inflammatory drugs (indomethacin) in reduction of ear edema and inhibition of neutrophil migration.
The major constituent isolated from the 3 extracts was chlorogenic acid (16), which presented better results when compared to literature reports that used the same experimental models.
Despite inhibiting neutrophil migration, infusion did not inhibit edema. Its composition similar to polar extract indicates that an antagonist is obtained by the extraction process. Thus, the polar extract presented high potential to develop an anti-inflammatory drug.
Vernonia spp.
Several species of Vernonia genus are used in folk medicine to treat various diseases. Recently studies have been published about these species for anti-inflammatory, antipyretic, anticancer, and antimalarial activities.
Vernonia scorpioides , popularly known as São Simão herb, is a Brazilian species that grows on poor and deforested soils all over the country and is widely used to treat different skin conditions such as lesions, irritations, ulcers, etc. To confirm the use of the species, Rauh et al. [116 ] evaluated the ethanolic extract of their flowers and leaves against 2 models of ear edema: acute, 12-tetracanoylphorbol acetate and arachidonic acid-induced and in a chronic model (with multiple applications of Croton oil), with evaluation of MPO inhibition. The ethanolic extract reduced dose-dependent edema in both cases, and MPO activity reduced in the acute model and in all evaluated parameters in the chronic model.
Da Silva et al. [114 ] also studied the anti-inflammatory potential of Vernonia condensate , popularly known as “Alumã”. They evaluated, among other activities, the anti-inflammatory capacity of the species through inhibition of proinflammatory cytokines production in LPS-induced cells of the Raw 264.7 strain. The ethyl acetate fraction from the ethanolic extract was able to inhibit the NO, IL-6, and TNF-α production in concentrations between 10 and 20 µg/mL. Its major component is 1,5-dipheoylquinic acid, although apigenin, luteolin, and chlorogenic acid have also been isolated. Anti-inflammatory potential was attributed to the antioxidant or inhibitory capacity of pro-inflammatory cytokines.
To the Vernonia patens species, anti-inflammatory activity was also attributed, through the decrease of ear edema induced by the administration of 13-acetate, 12-O-tetradecanoylphorbol, after application of hexane, ethyl acetate, and methanol extracts of stems and leaves. The hexane, ethyl acetate, and methanol stem extracts obtained inhibitions of 75, 22, and 80% respectively. For the leaves, the inhibition results were 31, 57, and 50% in the same solvents respectively.
Vernonia polyanthes has been widely used in Brazil to treat inflammatory diseases and cutaneous injuries. Thus, Minateli et al. [115 ] proved the antiedematogenic potential of ethanolic extract and ethyl acetate fraction of V. polyanthes branches when topically applied to the ears of mice previously induced with Croton oil, arachidonic acid, and phenol. The anti-inflammatory response was attributed to the inhibition of inflammatory mediators, which are known to be recruited by 13-acetate-12-O-tetracanoylphorbol present in Croton oil, where the response was most evident.
Comparison between Methods Used for Pharmacological Evaluation of Anti-Inflammatory Activity or Potential in the Compositae Family
Comparison between Methods Used for Pharmacological Evaluation of Anti-Inflammatory Activity or Potential in the Compositae Family
Although the in vitro assays present a good indication of the anti-inflammatory potential, in vivo assays are still the most used. Despite all legal requirements, such as the ethics committee for animal testing, this type of experiment can evaluate the action mechanism of tested substances and consider all the variables of the living organism that act in the system.
No in vitro methods are available to evaluate certain pathological conditions; thus, different methods of evaluation were observed, and in vivo tests are required, especially when investigating specific anti-inflammatory activities such as arthritis and asthma.
[Table 2 ] compiles the tests used in most of the references found. Among the in vivo methods of evaluation of anti-inflammatory activity, the most used were paw and ear edema. Another highly referenced model was carrageenan-induced peritonitis.
Table 2 In vitro and in vivo methods of the anti-inflammatory evaluation used in research with the Compositae family.
Assays
In vitro
Evaluation of inhibition of NO production in lipopolysaccharide-induced macrophages
[30 ]
Inhibition of COX and PGE
[33 ]
Leukocyte modulation and viability and production of cytokines and NO
[23 ]
Inhibition of NF-κ B
[45 ]
In vivo
Carrageenan-induced paw edema
[132 ]
Croton oil-induced ear edema
[132 ]
Peritonitis induced by lipopolysaccharide
[132 ]
Pleurisy induced by carrageenan
[89 ]
Model of induced arthritis
[65 ]
Model of induced asthma
[50 ]
Induced mucositis
[37 ]
Wound healing assay
[102 ]
Formalin test (inflammatory phase)
[93 ]
Psoriasis treatment (clinical trial)
[36 ]
Only 1 reference presented a model of asthma as an allergic inflammatory condition, where the species Eclipta prostrata was decreased bronchial hyperresponsiveness [50 ].
A model of induced arthritis was also successful in the response of the species Heliopsis longipes when its hexane extract rich in espilantol was evaluated in rodents [65 ].
The in vitro methods of anti-inflammatory potential evaluation include leukocyte viability tests and effects on the release of inflammatory or pro-inflammatory mediators such as interleukins, cytokines, and TNF-α , evaluation of inhibition of NO, COX and PGE inhibition assay, and NF-κ B assay [23 ], [30 ], [33 ], [45 ].
Pharmaceutical Forms or Types of Inputs Used in the Research about Anti-Inflammatory Activity or Potential of the Compositae Family
Pharmaceutical Forms or Types of Inputs Used in the Research about Anti-Inflammatory Activity or Potential of the Compositae Family
According to data extracted from [Table 1 ], the raw extracts, prepared under different methods and with the different solvent types, according to the polarity of the phytochemicals of interest, were the most used inputs in the research of anti-inflammatory activity of Compositae species, followed by the isolated substances, and, in equal percentage, the semi-solid pharmaceutical forms as gels and creams. The percentage of distribution by pharmaceutical forms or other inputs found in the articles is present in [Fig. 4 ], totaling 108 references contemplating these terms.
Fig. 4 Percentage distribution of the pharmaceutical forms and inputs described in the references found for Compositae species with anti-inflammatory action.
Few articles dealt with pharmaceutical forms in their experiments. De Carli et al. [100 ] demonstrated anti-inflammatory activity of Sphagneticola trilobata when testing kaurenoic acid, isolated from this species, from acetone extracts of roots, incorporated in base cream. Creams based on kaurenoic acid incorporated into Lanette® anionic bases, using concentrations of different types of skin permeation promoting agents, were evaluated by mouse ear edema, induced by Croton oil. Creams using kaurenoic acid with isopropyl myristate and soy lecithin as permeation enhancing agents had edema inhibition results similar to the positive dexamethasone control.
Kaurenoic acid activity was also evaluated in a semi-solid product containing 1% dry extract of S. trilobata standardized in kaurenoic acid. The use of the product reduced ear edema and inhibited neutrophil migration. Thus, it is an important prototype for the development of topical anti-inflammatory products [99 ].
Heidari et al. [111 ] incorporated ethanolic extract of Tragopogon graminifolius into Eucerin emulsifying base, where the recognized anti-inflammatory activity of the flavonoids present in the extract could have favored the healing of the wounds.
Samanta et al. [102 ] also proposed a silibinin gel of Silybum marianum 2%, a potent wound healing agent, where after 14 days of application in rats, the lesion was approximately 96% lower than the base gel (~ 87%) and the standard gel (~ 98%).
The search for more classic pharmaceutical forms, such as drug solutions, found ethanolic or aqueous extracts, among others, of Smallanthus sonchifolius for direct application as topical use, for example, in ear edema as described by Oliveira et al. [88 ]. Among the assayed extracts, the extract obtained by rinsing the leaves with acetone presented the highest percentage of ear edema inhibition (44%) when applied in mice induced by croton oil. This response was attributed to the sesquiterpenolactones present in the leaves of S. sonchifolius , as well as chlorogenic acid, although the former had a more pronounced effect.
However, for phytotherapy, the most traditionally used oral forms are teas and syrups, where there were few studies. In traditional Australian medicine, for example, species such as Tussilago farfara (leaves) are used in the form of teas to treat respiratory and cutaneous infections as well as for rheumatism and gout [113 ]. According to Brazilian legislation [10 ], medicinal teas can be registered as traditional phytotherapeutic products, provided they are produced in the form of infusion, decoction or maceration in water by the consumer, according to the FFFB [9 ], but few references were found that mention this form.
Conventional pharmaceutical forms are the most commonly found contemplating the anti-inflammatory activity of the Compositae family without major incremental innovations. Only 1 reference was found mentioning the liposomal form for extracts of Arnica sp., which presented superior anti-inflammatory potential to the non-encapsulated form [27 ]
Patents Targeting Products with Anti-Inflammatory Activity from Compositae Species
Patents Targeting Products with Anti-Inflammatory Activity from Compositae Species
The search for patents in the Derwent database, in contrast to the searches in the other databases, was extended to 20 y, considering the period of patentsʼ validity.
Although some patents fall into more than 1 IPC classification, only those with at least A61 (medical or veterinary science, hygiene), A61K (preparations for medical, dental, or hygienic purposes) or A61P (therapeutic medicinal preparations) were evaluated.
Not all the patents described the part of the plant used, indicating that the whole plant, or simply the plant, had been used. When the patents described the markers of the species used by the class of secondary metabolites, this information is indicated in [Table 3 ]. Some patents referenced the mechanism of action, where many times the species or isolated substances acted on the eicosanoid cascade.
Table 3 List of patents found in Derwent database involving process development or products of Compositae species with anti-inflammatory activity.
Patent Number
Country of deposit
Species
Part(s) of the plant(s) used
Process/Product
Scientific Marker
Reference/ Inventor
EP3331541-A4; US2018221425-A1
Europe, United States
Calendula sp. Achillea millefolium L.
Helichrysum sp.
–
Infuse, tincture
–
[133 ]
EP3042662-A1; FR3031458-A1
Europe France
Lactuca sativa subsp. capitata (L.) Schübl. & G. Martens, Lactuca sativa subsp. crispa (L.) Schübl. & G. Martens or Lactuca sativa subsp. longifolia (Lam.) Alef, among other lettuce species of other families
Leaves
Extract in form of gel, milk, cream, lotion, emulsion, oil, balm or ointment, or oral in the form of tablets, capsules, ampoules, syrups, or drops
Polyphenolic compounds (caffeoyl tartaric acid, caffeic acid, chlorogenic acid, chicoric acid)
[134 ]
FR3019041-B1
France
Centaurea sp.
Seeds
Processes of extraction The composition is in form of cream, gel, lotion, milk, etc., comprising active agent in encapsulated form, like microspheres, liposomes, nanoparticles, nanocapsules, etc.
–
[135 ]
BR102015024304-A2
Brazil
Baccharis glaziovii Baker
Leaves and flowers
Extract prepared in galenic liquid, semi-solid solutions, suspensions, emulsions, aerosol, powders, capsules, pills and tablet forms
–
[136 ]
ES2533200-B1; US2016213724-A1; EP3052112-A1
Spain, United States, Europe
Calendula officinalis L.
Whole Plant
Aqueous extract for topical composition utilization
–
[137 ]
US2017319467-A1; EP3250295-A2
United States, Europe
Baeriopsis sp.
Plant cells (in vitro culture), or ground material containing phytoalexin
Cosmetic composition, for topical application
phytoalexin
[138 ]
AU2008322737-A1; CA2705642-A1; EP2219655-A2; CN101878033-A; US2011008476-A1; JP2011503161-W; IN201001473-P2
Australia, Canada, Europe, China, United States, Japan, India
Helianthus sp. or Helianthus annus L.
–
Glucan derived from yeast derived from Compositae
Glucan
[139 ]
MX2009001657-A1
Mexico
Matricaria chamomilla L.
Plant
Extract
–
[140 ]
KR2014088504-A
Republic of Korea
A. spathulifolius Maxim., C. morifolium Ramat., C. boreale (Makino) Makino, C. indicum L., C. drummondii (D.Don) Torr. & A. Gray and R. laciniata L.
Plant
Extracts
–
[141 ]
FR2807319-A1; AU200146631-A
France, Australia
Arnica montana L., Tanacetum parthenium (L.) Sch. Bip. or Cnicus benedicticus L.
Plant
Extract
Sesquiterpene lactone (helenalin, dihydrohelenalin, parthenolide, cnicin) and their derivatives
[142 ]
BR200409179-A; KR2005121239-A; AU2004228021-B2; JP4769184-B2; CN1798568-B; KR1151322-B1; US9622964-B2; EP1631304-A4
Australia, Europe, Brazil, Republic of Korea, Japan, China, United States
Achyrocline sp., Anaphalis sp., Cotula sp., Gnaphalium sp., Helichrysum sp., Centaurea sp., Eupatorium sp., Baccharis sp.
Stems, roots, root barks seeds, rhizomes, flowers etc.
Pharmaceutical, dermatological or cosmetic formulation, solution, cream, lotion, ointment, gel or emulsion, liquid, paste, a soap or powder.
Gallate, acetate, cinnamoyl, hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters or caffeoyl esters
[143 ]
JP2012158528-A
Japan
Silybum marianum (L.) Gaertn.
Seeds
Extracts
–
[144 ]
JP2017124984-A
Japan
Cynara scolymus L., Centaurea cyanus L.; Silybum marianum (L.) Gaertn.; Helianthus annuus L., Tanacetum vulgare L., Tanacetum parthenium (L.) Sch. Bip. or Achillea millefolium L., Cichorium intybu L.
Whole Plants
Internal composition or topical formulation
–
[145 ]
EP2436757-A2; KR1212032-B1; RU2011152866-A
Republic of Korea, Europe, Russian Federation
Chrysanthemum morifolium Ramat, Artemisia sp.
Stem cell
Capsule
–
[146 ]
KR1537847-B1
Republic of Korea
Aster spathulifolius Maxm., Chrysanthemum morifolium Ramat, C. boreale (Makimo) Makino, C. indicum L., Coreopsis drummondii (D. Don) Torr & A. Gray and Rudbeckia laciniata L.
Whole plant
Extracts
–
[147 ]
AU2003239875-A1
Australia
Calendula officinalis L.
Whole plant
Cell juice as formulation ingredient for topical application
–
[148 ]
US2003175235-A1; US7442391-B2; AU2017202660-A1
United States, Australia
Calendula officinalis L., dentre outras espécies de outras famílias
Flowers
Cellular juice extracted from plant biomass for topical application
–
[149 ]
US8101212-B2
United States
–
Whole plant
Cosmetic composition comprises a membrane fraction derived from cell juice extracted from fresh plant biomass
–
[150 ]
US8663712-B2
United States
Calendula officinalis L.
Flowers
Cosmetic formulation for topical application
–
[151 ]
US8734861-B2
United States
Calendula officinalis L.
Flowers
Cosmetic composition comprises a membrane fraction derived from cell juice extracted from fresh plant biomass
–
[152 ]
US2014295004-A1
United States
Calendula officinalis L., among other species of other families
Flowers
Hydrophilics cream base, lotion base, surfactant base and cream base, or hydrophobic surfactant base
–
[153 ]
TW201521755-A; CA2900517-A1; KR2015127252-A; CN105007988-A; US2016000851-A1; SG11201506444-A1; EP2969024-A1; IN201507664-P1; AR95439-A1; JP2016516679-W; MX2015011475-A1; BR112015020178-A2; SG10201707422-A1; AU2014231030-B2; ID201703645-A
Australia, Taiwan, Canada, Republic of Korea, China, United States, Singapore, Europe, India, Argentina, Japan, Mexico, Brazil
Calendula officinalis, Tanacetum parthenium (L.) Sch. Bip., Matricaria chamomilla L.
Whole plant
Cream, dressing, gel, lotion, ointment, liquid, spray applicator, and their combinations, or wash-off product (liquid hand soap, bar soap, body wash, shampoo)
polyphenols
[154 ]
JP6246993-B2
Japan
Anthemis sp.; Arctium lappa L.
Whole plant
–
–
[155 ]
DE102017002005-A1
Germany
Solidago sp.; Artemisia sp.
Whole plants
Cream, paste, ointment and gel, liquid form, as emulsion, lotion, solution, tincture, extract, tea and dispersion or mixture and gel, solid form, emulsion, lotion, aerosol or spray
–
[156 ]
US2001024664-A1; EP1401461-A2; JP2004532811-W; AU2002230985-A8
United States, Australia, Europe, Japan
Artemisia sp., Aster sp., Blumea sp., Cichorium sp., Crassocephalum sp., Silybum sp., Sonchus sp. or Taraxacum sp.
Plant
Extracts
–
[157 ]
US2004185122-A1
United States
Artemisia spp., Aster spp., Blumea spp., Cichorium spp., Crassocephalum spp., Silybum spp., Sonchus spp., and Taraxacum spp.
Whole plants
Extracts
–
[158 ]
JP2014129253-A
Japan
Matricaria , preferably M. chamomilla L.
Whole plants
Tablet, pill, granule, capsule, emulsion, liquid agent, gel, syrup, or solid state composition
–
[159 ]
US2008311230-A1
United States
Artemisia absinthium L., Artemisia annua L., Artemisia vulgaris L., Artemisia capillaris Thunb.
–
–
–
[160 ]
MX2013004050A
Mexico
Matricaria chamomilla L. in association
Whole Plant
Liquid or solid form
[161 ]
JP2018062468-A
Japan
Compositae family plant
Flower
Extract of flowers in the form of paste, gel. Powder, granules, tablet, capsule, chewable tablet, stick or syrup is administered by oral route
–
[162 ]
JP6255154-B2
Japan
Arctium lappa L.
Whole Plant
External preparation
glycyrrhetic acid
[163 ]
CN107753666-A
China
Chrysantemum sp.
Flowers
Liquid
–
[164 ]
US6749871-B2
United States
Wyethia amplexicaulis (Nutt.) Nutt., Balsamorhiza sagittata (Pursh) Nutt., Helianthella uniflora (Nutt.) Torr. & A. Gray, or Tragopogon dubius Scop.
Part of plant
Capsules
–
[165 ]
DE102015102020-A9; CA2976583-A1; EP3256142-A1; US2018036360-A1; CN107889461-A
Germany, Canada, Europe, United States, China
B. alba (L.) DC., B.pilosa L., among other species of other families
Whole plants
The extracts can be in a form of solution, dispersion, suspension, emulsion, tincture, syrup, juice, tea, tablet, powder, coated tablet, granule, lyophilisate, capsule, aerosol, spray, lotion or cream
Flavonoids, saponins, iridoids, polyphenols, polysaccharides, glycosylate, terpenes, monoterpenes sesquiterpenlactone, proazulene, carotenoids, vitamins A, B, C, D and E, amino acids, and/or minerals
[166 ]
As in the research in scientific databases, when the keyword Compositae was searched many more references were found than when the anti-inflammatory activity of the family was searched; however, this information was used as a beacon for our findings.
When the terms Compositae and anti-inflammatory activity were combined (27), a small number of patents was found compared to the same research done for articles, dissertations, and theses, which indicates the low exploitation of this research for industrial pharmaceutical market products.
Taking into consideration that this family has many records of medicinal activity, including the anti-inflammatory activity as described in the literature, and based in their traditional use, the development of their products is necessary. [Table 3 ] presents the data found in Derwent database for the search of patents involving Compositae species with anti-inflammatory activity and their products.
Patent research for pharmaceutical forms found a low number of registrations, as can be seen in [Fig. 1 ]. When patents are explored, their developments can extend and transform other pharmaceutical forms, as can be observed in [Table 3 ].
One of the patents found in this search involving the terms Compositae and anti-inflammatory activity was first deposited in the United States and Australia by Koganov, where different numbers of registries occurred because filings were made along different years or using different depositors, but performed by the same inventor. Thus, Koganov initially filed in 2003 [149 ] the patent in the records US2003175235-A1; US7442391-B2; and AU2017202660-A1. Subsequently, beginning in 2009, Akzo Nobel started to register the same patent exclusively [150 ] and to maintain it in the following years, with the last filing made in 2014 [153 ]. It is a composition based on membrane fractions obtained from cellular juice extracted from the biomass from the fresh plants of different families, including Compositae, where Calendula officinalis is the representative of this group. This membrane
fraction presents antiproteolytic activity, inhibits cell growth activity, can be used as a skin anti-inflammatory, incorporated in the form of hydrophilic cream for topical use, and presents as a mechanism of action the inhibition of neutrophil elastase, trypsin, and gelatinase B. This same composition was deposited under the cosmetic aspect, therefore addressing other classifications in the IPC.
Another patent found with this combination of keywords was filed in Europe and France approaching the use of the leaf extract of lettuces, such as the species Lactuca sativa , rich in polyphenolic compounds, with anti-inflammatory activity, which can be incorporated into creams, gels, balms, oils, and other pharmaceutical forms for topical use and incorporated into internal use pharmaceutical forms, such as capsules, tablets, syrups, etc. It was found in some of those combinations of terms [134 ].
One of the records found presented a patent covering species from 3 different families, among them Bidens pilosa, for the formation of a phytomixture to treat inflammatory conditions of the skin [166 ], which inhibits 5-LOX as an anti-inflammatory mechanism of action.
While using such terms, a Japanese patent was found to prevent and treat inflammation as dermatitis using Matricaria preferably, M. chamomilla
[159 ]. The latter 2 were also identified in the search combining terms of Compositae and anti-inflammatory activity for pharmaceutical syrup.
No records were found using only the words “Compositae” and “pharmaceutical preparations”. The same thing happened when we searched forms such as solutions or medical suspensions, as well as for compresses. Some patents consulted presented the terms in the abstract extension, such as solution and suspension, for example. However, when we exchanged these dosage forms for capsules or tablets, the same record already mentioned, based on Lactuca sativa
[134 ] was found.
When the investigations involved the terms anti-inflammatory activity and semisolid, no records were observed. When we replaced the term semisolid with the pharmaceutical cream form, the number of patents for this combination increased; however, all the records found had also been observed in previous searches without involving a pharmaceutical form, but only by anti-inflammatory activity. For the gel form, the searches presented a patent that was not yet found, also from the researcher Koganov, using species like Calendula officinalis, Tanacetum parthenium, and Matricaria chamomilla , in composition, to reduce the inflammatory state of the skin [154 ] with an anti-inflammatory mechanism of action that inhibited of IL-8 and IL-1 secretion.
Using the terms Compositae and nanoformulations, only 1 record was found for the nanoparticle term from the researcher Bernard et al. [135 ]. They patented the process of obtaining extract of the species Centaurea sp. under the registration number FR3019041-B1 to treat and prevent inflammatory disorders of the skin and hair, among others.
In addition to these patents found in Derwent, in isolated research, we found the patent on the development of a mucoadhesive product from the Bidens pilosa species deposited both in Brazil and in the World Intellectual Property Organization (WIPO), which is a self-funding agency of the United Nations, with 192 member states: “Anti-inflammatory, proliferative, protective and mucoadhesive, soluble and stable pharmaceutical compositions; its use in the treatment of mucositis and the obtaining process; basic pharmaceutical composition for the preparation of the pharmaceutical compositions and process of obtaining”, under registers of WO 2016065442A1 [167 ] and BR 10 2013 003316 A2 [168 ]. Articles related to this patent were also found in the bibliographic references.
Some relevant results were found by searching only for the words Compositae and the pharmaceutical forms, without involving the anti-inflammatory activity. For example, in the search for Compositae and tablets, although no results were found when contemplating the anti-inflammatory activity, a Brazilian patent appeared that described the use of the species Baccharis glaziovii to treat ulcers in humans and animals [136 ], which is an inflammatory condition. Another patent was found with these terms based on species from Compositae such as Wyethia amplexicaulis, Balsamorhiza sagittata, Helianthella uniflora , or Tragopogon dubius for cystitis [165 ].
[Table 4 ] presents in the world context, the number of patents per country. For patents on products of the Compositae family with anti-inflammatory activity, Brazil, Canada, and Germany are at the same level in the ranking (3).
Table 4 Patents deposited by countries on the Compositae family, in the Derwent Innovation Index database in conjunction with isolated research.
Countries (Codes)
Number of Patents
Argentina (AR)
1
Australia (AU)
7
Brazil (BR)
3
Canada (CA)
3
China (CN)
5
European Patent Organization (EP)
10
France (FR)
3
Germany (DE)
2
India (IN)
2
Japan (JP)
10
Mexico (MX)
3
Republic of Korea (KR)
5
Russian Federation (RU)
1
Singapore (SG)
1
Spain (ES)
1
Taiwan (TW)
1
United States (US)
16
As expected, the world ranking is led by the United States (16), followed by Japan and European Union (10), and Australia (7). Although these powers present expressive numbers of patents, the results are still very low when compared to the research done, demonstrating the urgent need to encourage development of technological products.
Technology Products on the Market from Compositae to Anti-inflammatory Activity
Technology Products on the Market from Compositae to Anti-inflammatory Activity
Even though countless studies evaluate the potential anti-inflammatory activity of herbal medicines from the biodiversity and companiesʼ websites advertise producing herbal products, where descriptions of several of them were found, when consulting regulatory agencies such as the Brazilian Health Regulatory Agency (ANVISA), many products that had been registered were found to be currently in a situation of expired or canceled registration. Products based on arnica (Arnica montana ), chamomile (Matricaria chamomilla ), calendula (Calendula officinalis ), guaco (Mikania glomerata ), baccharis (Baccharis trimera (Less.) DC.), globe artichoke (Cynara scolymus ), among others have been canceled [169 ].
Among the 23 artichoke products registered with ANVISA, only 5 have valid records, in pharmaceutical forms such as tablets and capsules. Arnica included 16 products contemplating the use of its popular synonymy; however, only 5 have valid records (ointments, gels and solutions), most of which came from Arnica montana , an exogenous species. The only 2 products found with its substitute S. chilensis were master products (cream and gel) produced by the Health Department of Rio de Janeiro [170 ]. Regarding the guaco (Mikania glomerata ), despite having already presented 9 records, currently 7 are valid (syrups and solutions) (i.e, only 2 have expired). The milk thistle (Silybum marianum ) presented only 3 valid products such as tablets.
In addition to these, for the products based on other known anti-inflammatory species, the result of the search terms of products is closer to the number of patents and products. In spite of these numbers, several products were found being commercialized and even advertised on companiesʼ websites, although without certainty about their proper registration.
Survey of the Technological Potential of the Compositae Family with Anti-inflammatory Activity or Potential
Survey of the Technological Potential of the Compositae Family with Anti-inflammatory Activity or Potential
[Fig. 5 ] presents a survey of the Compositae species most cited in the literature, based on the number of references that prove their action, patents requested or registered involving extraction and isolation processes or product development from these species, and commercialized technological products originated from them, whose records are valid at ANVISA. This comparison sought to diagnose commercial use for the Compositae family, based on the scientific background or portfolio, drawing attention to the technological potential of some species of this family, which have been neglected by the phytotherapeutic market.
Fig. 5 Comparison between bibliographic references, patents, and products of certain species from Compositae with anti-inflammatory activity: Arctium spp. (A. lappa and A. minus ); Arnica spp. (Arnica montana, Solidago chilensis, Tithonia diversifolia, Lychonophora passerina, Chromolaena odorata ); Artemisia spp. (A. herba-alba, A. judaica and A. pallus ); Baccharis spp. (B. incarum, B. boliviensis, B. trimera, B. uncinella ); Bidens spp. (B. tripartita and B. pilosa ); Mikania spp. (M. cordata, M. glomerata, M. lindleyana, M. micantha); Vernonia spp. (V. condensata, V. polyanthes, V. scorpioides ).
As a result, it was possible to observe that, in terms of citations in bibliographical references, Arnica, in all its synonyms appeared in a greater number (20), which did not reflect in terms of patents (1) and its products (5) marketed. The species Calendula officinalis presented the largest number of patents (8); however, just 1 article proving its pharmacological activity was found and 1 officially registered product on the market. The species Mikania sp. presented a similar number of bibliographical citations about its activity (5) in relation to the products found in the market (7) but did not present any patent request. The Baccharis and Bidens pilosa species presented some scientific references and patent applications; however, no product was detected on the market. The species Matricaria chamomilla was also a surprise, since it only presented 1 reference, 1 patent application, and 1 product; nevertheless, this species is mentioned
in the MFFB and FFFB [8 ], [9 ] for external use as anti-inflammatory. This may be due to the traditional knowledge about these species, which are treated as medicinal herbs by traditional communities and are widely used in folk medicine.
Despite the ethnopharmacological studies that empirically prove the use of these and other Compositae species as anti-inflammatory, and the advent of herbal medicine in Brazil in the 2000 s, still more than 10 y after the main legislation and public policies that recognize and implement this therapy [171 ], [172 ], many species have not been commercialized by the pharmaceutical industries.
The species Cynara scolymus may be an isolated fact. Although only 1 scientific article referred to its anti-inflammatory activity and no patent application, 5 products are on the market with this species. However, the commercial appeal in most of these products refers to their action for liver problems.
Conclusion
This is a consistent study that presents safe results to guide and to direct future research on anti-inflammatory agents and the technologies added to the products related to the Compositae family.
Our findings revealed that drug solutions, gels, suspensions, syrups, compresses, and creams, with minor citations, were the most cited terms in the reference survey, although creams appeared as the most cited one in the patents database. Otherwise, nanoparticles presented just 1 citation, demonstrating few studies on specific nanoformulations and that the conventional pharmaceutical forms are still the most studied ones.
These data were ratified when we found extracts, tinctures, and essential oils as the most cited inputs, followed by purified fractions and isolated substances, creams, and gels and in a minor proportion, the liposomes.
Different pharmacological assays have been performed to demonstrate the anti-inflammatory activity or potential of the Compositae family, and many of them have had their popular use ratified on a scientific basis. However, the data confirmed the predominance of certain species from Compositae family for anti-inflammatory activity, such as arnica, guaco, calendula, chamomile, artichoke, as well as also by their traditional use, being described in official compendia such as FFFB and MFFB.
Arnica spp. was the species most cited in the references while Calendula officinalis presented a higher number of patents. Syrups based on Mikania spp. were the most products found at the ANVISA website.
Although many species having scientifically proven anti-inflammatory action, no feasible products have been developed with quality control, stability, and pharmacological assays, and especially with registration with the healthcare authority in Brazil, ANVISA.
The United States holds the largest number of patents involving the searched terms, followed by the European Union and Japan, and Australia; however, the numbers were still small.
The low number of patents and products may be related to the survey having been performed in only a single database; nevertheless, it evidences minimal effort for technological development and commercial exploitation of this family. These data reinforce the need to develop skills and fill technological gaps to foment research and innovation in biodiversity products.
This study updates search results and presents products that have a valid registration today.
Contributors’ Statement
Conception and design of the work: D. C. D. X. P. Lopes, E. Ricci-Junior, S. S. Valverde; data collection: D. C. D. X. P. Lopes; analysis and interpretation of the data: D. C. D. X. P. Lopes, T. Oliveira, A. L. Viçosa, S. S. Valverde, E. Ricci-Junior; drafting the manuscript: D. C. D. X. P. Lopes; critical revision of the manuscript: D. C. D. X. P. Lopes, T. Oliveira, A. L. Viçosa, S. S. Valverde, E. Ricci-Junior.